Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Cannara Biotech Inc (OP: LOVFF )

0.4929 +0.0674 (+15.84%)
Streaming Delayed Price Updated: 1:18 PM EST, Nov 25, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Cannara Biotech Inc

< Previous 1 2 Next >
Canadian Cannabis Producer Cannara Reports 43% YoY Revenue Growth, Boosts Market Share And Profitability
Vertically integrated cannabis producer Cannara Biotech Inc. (TSXV: LOVE) (OTCQB: LOVFF) (FRA: 8CB0) announced on Monday its fourth quarter and full fiscal 2024 financial and operating results ended... 
Via Benzinga
Topics Cannabis
Exposures Cannabis
Cannara Biotech Inc. Reports Q4 and Fiscal Year 2024 Results: Achieves Record Sales Growth and Operating Cash Flow, Solidifying Leadership in Canada's Cannabis Market
From Cannara Biotech (Québec) Inc.
Via GlobeNewswire
Canada's Cannabis Market Goes Cold, Pot Prices Hit Bottom: Why Top Producers Are Losing Ground
Amid this slowdown, certain products capture consumer interest, even as prices stabilize and competition intensifies. 
Via Benzinga
Topics Cannabis
Exposures Cannabis
Cannara Biotech Reports 6% YoY Drop In Q3 Gross Profit, 22% Revenue Increase As It Enhances Sales Force And Infrastructure
Vertically integrated cannabis company Cannara Biotech Inc. (TSXV: LOVE) (OTCQB: LOVFF) (FRA: 8CB0) announced on Tuesday its fiscal third quarter 2024 financial and operating results for the three and... 
Via Benzinga
Topics Cannabis
Exposures Cannabis
Cannara Biotech Reports Q3 2024 Financial Results
From Cannara Biotech (Québec) Inc.
Via GlobeNewswire
Cannabis Slowdown In Canada: Analyst Spotlights What Still Sells And Where The Money Is Going
In a recent report, Pablo Zuanic of Zuanic & Associates analyzed trends in Canada's recreational cannabis market through May 2024. The report highlights a deceleration in market growth and notable... 
Via Benzinga
Topics Cannabis
Exposures Cannabis
Cannara Biotech Reports 51% YoY Revenue Increase In Q2, Wider Net Loss
Cannara Biotech Inc. announced on Monday its fiscal second quarter 2024 financial and operating results for the three and six-month periods ended Feb. 29, 2024. The company reported a 68%... 
Via Benzinga
Topics Cannabis
Exposures Cannabis
This Cannabis Producer Reports It Is Able to Deliver Some Of The Highest Quality Product To Market At Some Of The Most Competitive Prices
--News Direct-- 
Via News Direct
Topics Cannabis
Exposures Cannabis
The 7 Most Undervalued Cannabis Stocks to Buy in December
These seven cannabis stocks are either undervalued based on traditional metrics, or are undervalued relative to future potential. 
Via InvestorPlace
Topics Cannabis
Exposures Cannabis
This Cannabis Producer Reports It Is Able to Deliver Some Of The Highest Quality Product To Market At Some Of The Most Competitive Prices
Nicholas Sosiak, CFO of Cannara Biotech (TSXV: LOVE.V) (OTCQB: LOVFF) (FRA: 8CB) was recently interviewed by Benzinga. 
Via Benzinga
Topics Cannabis
Exposures Cannabis
Bearish Sentiment Across The Cannabis Space - Check Full Movers For August 21, 2023
Via Benzinga
Topics Cannabis
Exposures Cannabis
7 Smoking-Hot 420 Stocks to Buy in 2023
A blaze of renewed bullishness may be just around the corner for these seven cannabis plays, making them top 420 stocks to buy. 
Via InvestorPlace
Topics Cannabis
Exposures Cannabis
Cannabis Stock Movers For August 10, 2023
Via Benzinga
Topics Cannabis
Exposures Cannabis
Cannara Biotech Q3 FY23 Net Revenue Grows 57% YoY, What About Adjusted EBITDA?
Cannara Biotech Inc. 
Via Benzinga
Cannabis Stock Gainers And Losers From July 25, 2023
Via Benzinga
Cannabis Stock Gainers And Losers From August 4, 2023
Via Benzinga
Cannara Biotech Secures An Additional $10M In Non-Dilutive Capital With Its Lead Credit Provider, BMO Commercial Banking
Cannara Biotech Inc. 
Via Benzinga
Cannara Biotech Q2 FY23 Revenue Grows 76% YoY To $9.6M, Here Are The Details
Cannara Biotech Inc. (OTCQB: LOVFF) (TSXV:LOVE) (FRA:8CB) released its fiscal second quarter 2023 financial results, revealing net revenue of CA$13 million ($9.6 million), a 76% increase, compared to... 
Via Benzinga
Marijuana Stock Movers For August 1, 2023
Via Benzinga
Olymbec Investments Increases Its Ownership In Cannara Biotech
Cannara Biotech Inc. (OTCQB: LOVFF) (TSXV:LOVE) (FRA:8CB) held its annual shareholder meeting on January 25, 2023. 
Via Benzinga
Cannara Biotech Q1 Revenue Grows 57% YoY To $7.7M, What About Adjusted EBITDA?
Cannara Biotech Inc. (OTCQB: LOVFF) (TSXV:LOVE) (FRA: 8CB) released its fiscal first quarter 2023 financial results for the three-month period ended November 30, 2022, revealing revenue of CA$10.3... 
Via Benzinga
Cannabis Stock Movers For July 27, 2023
Via Benzinga
Cannara Biotech Q4 Revenue Grows 84% YoY To $8.9M
Cannara Biotech Inc. (OTCQB: LOVFF) (TSXV:LOVE) (FRA:8CB) released its fiscal fourth quarter and fiscal year 2022 financial results for the three-month and full year periods ended August 31, 2022,... 
Via Benzinga
Cannara Biotech Enters Into The British Columbia Cannabis Market And Launches New Products
Cannara Biotech Inc. (OTCQB: LOVFF) (TSXV:LOVE) (FRA:8CB), a Quebec-based, vertically integrated producer of cannabis and derivative product offerings, entered into the British Columbia (BC) market. 
Via Benzinga
Cannara Biotech Signs An Exclusive Brand Partnership With Exotic Genetix In Canada
Cannara Biotech Inc. (OTCQB: LOVFF) (TSXV:LOVE) (FRA: 8CB) entered into an exclusive brand partnership with Exotic Genetix Ltd. 
Via Benzinga
Cannara Biotech Revenue Grows 41% YoY, Here Are The Details
Cannara Biotech Inc. (OTCQB: LOVFF) (TSXV:LOVE) (FRA:8CB) fiscal Q3 2022 revenue was $10.1 million, a 36% increase from the previous quarter and a 41% increase compared to Q3 2021. 
Via Benzinga
Cannara Biotech Closes $50 Million Credit Facility Led By BMO Commercial Banking
Cannara Biotech Inc. (OTCQB: LOVFF) (TSXV:LOVE) (FRA:8CB) has closed on a $50M credit facility led by BMO Commercial Banking. 
Via Benzinga
Cannara Biotech Revenues Grew 229% To $7.4M In Q2 2022 YoY
Cannara Biotech Inc. (OTCQB: LOVFF) (TSXV:LOVE) (FRA: 8CB) released its fiscal second quarter 2022 financial and operating results for the three and six-month periods ended February 28, 2022. 
Via Benzinga
The Week In Cannabis: Isiah Thomas, Tilray, The DEA, Ohio, Mexico And More
Below is a recap of the main news related to the cannabis industry and markets for the week of December 6, 2021. 
Via Benzinga
Topics Cannabis
Exposures Cannabis
Cannara Biotech Shares Surge On 983% QoQ Revenue Growth, Positive Adjusted EBITDA
Vertically integrated cannabis company Cannara Biotech Inc. (TSXV: 
Via Benzinga
Topics Cannabis
Exposures Cannabis
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.